Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Price

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Biochemical Pharmacology|November 13, 2016
In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulationJennifer E Sager, Sasmita Tripathy, Lauren S L Price, et al.
Journal of Evolutionary Biology|January 15, 2014
Renewed diversification is associated with new ecological opportunity in the Neotropical turtle antsS L Price, S Powell, D J C Kronauer, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Factors Affecting the Pharmacology of Antibody-Drug ConjugatesAndrew T Lucas, Lauren S L Price, Allison N Schorzman, et al.
Plos One|March 6, 2014
Genomic and metabolomic insights into the natural product biosynthetic diversity of a feral-hog-associated Brevibacillus laterosporus strainChristine M Theodore, Blake W Stamps, Jarrod B King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 8, 2018
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouseM D McSweeney, T Wessler, L S L Price, et al.
The Oncologist|May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC TrialE Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
Therapeutic Advances in Medical Oncology|November 4, 2021
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse modelLauren S L Price, Judith N Rivera, Andrew J Madden, et al.
Acta Crystallographica. Section B, Structural Science|August 16, 2000
A test of crystal structure prediction of small organic moleculesJ P Lommerse, W D Motherwell, H L Ammon, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Biochemical Pharmacology|November 13, 2016
In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulationJennifer E Sager, Sasmita Tripathy, Lauren S L Price, et al.
Journal of Evolutionary Biology|January 15, 2014
Renewed diversification is associated with new ecological opportunity in the Neotropical turtle antsS L Price, S Powell, D J C Kronauer, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Factors Affecting the Pharmacology of Antibody-Drug ConjugatesAndrew T Lucas, Lauren S L Price, Allison N Schorzman, et al.
Plos One|March 6, 2014
Genomic and metabolomic insights into the natural product biosynthetic diversity of a feral-hog-associated Brevibacillus laterosporus strainChristine M Theodore, Blake W Stamps, Jarrod B King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 8, 2018
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouseM D McSweeney, T Wessler, L S L Price, et al.
The Oncologist|May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC TrialE Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
Therapeutic Advances in Medical Oncology|November 4, 2021
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse modelLauren S L Price, Judith N Rivera, Andrew J Madden, et al.
Acta Crystallographica. Section B, Structural Science|August 16, 2000
A test of crystal structure prediction of small organic moleculesJ P Lommerse, W D Motherwell, H L Ammon, et al.
Pageof 5